(CRBG) Corebridge Financial - Overview
Sector: Financial ServicesIndustry: Asset Management | Exchange NYSE (USA) | Currency USD | Market Cap: 11.843m | Total Return -24.8% in 12m
Stock: Annuities, Life Insurance, Investments, Retirement
Total Rating 21
Risk 73
Buy Signal -0.58
| Risk 5d forecast | |
|---|---|
| Volatility | 31.9% |
| Relative Tail Risk | -1.01% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.68 |
| Alpha | -44.41 |
| Character TTM | |
|---|---|
| Beta | 1.377 |
| Beta Downside | 1.649 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.52% |
| CAGR/Max DD | 0.68 |
EPS (Earnings per Share)
Revenue
Description: CRBG Corebridge Financial March 04, 2026
Corebridge Financial, Inc. (CRBG) offers retirement and insurance products in the United States. Its operations are divided into four segments: Individual Retirement, Group Retirement, Life Insurance, and Institutional Markets.
The Individual Retirement segment focuses on various annuity products, including fixed, fixed index, and variable annuities. The Group Retirement segment provides in-plan and out-of-plan services. In-plan offerings include recordkeeping platforms and annuity options, while out-of-plan services encompass annuities, investment advisory, and brokerage services. The broader financial services sector often sees companies offering a mix of these product types to cater to diverse client needs.
The Life Insurance segment sells term, whole, and universal life insurance. The Institutional Markets segment provides specialized products such as stable value wraps, structured settlement annuities, and guaranteed investment contracts. These products are generally tailored for corporate and institutional clients, a common practice in the institutional investment management business model.
For more detailed financial metrics and performance analysis, consider researching CRBG on ValueRay.
Headlines to watch out for
- Interest rate fluctuations impact annuity product profitability
- Equity market performance influences variable annuity sales
- Regulatory changes in insurance industry create compliance costs
- Demographic shifts affect demand for retirement solutions
- Competition from other financial institutions pressures market share
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -366.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -0.06 > 1.0 |
| NWC/Revenue: 1.51k% < 20% (prev 2.37k%; Δ -865.1% < -1%) |
| CFO/TA 0.00 > 3% & CFO 2.02b > Net Income -366.0m |
| Net Debt (10.46b) to EBITDA (567.0m): 18.45 < 3 |
| Current Ratio: 2.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (512.1m) vs 12m ago -10.32% < -2% |
| Gross Margin: 80.89% > 18% (prev 0.79%; Δ 8.01k% > 0.5%) |
| Asset Turnover: 0.72% > 50% (prev 0.69%; Δ 0.03% > 0%) |
| Interest Coverage Ratio: 0.02 > 6 (EBITDA TTM 567.0m / Interest Expense TTM 552.0m) |
Altman Z'' 0.86
| A: 0.11 (Total Current Assets 67.19b - Total Current Liabilities 23.65b) / Total Assets 413.55b |
| B: 0.04 (Retained Earnings 18.37b / Total Assets 413.55b) |
| C: 0.00 (EBIT TTM 11.0m / Avg Total Assets 401.47b) |
| D: 0.02 (Book Value of Equity 8.93b / Total Liabilities 399.59b) |
| Altman-Z'' Score: 0.86 = B |
Beneish M
| DSRI: 0.84 (Receivables 648.0m/713.0m, Revenue 2.89b/2.68b) |
| GMI: 0.98 (GM 80.89% / 79.31%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 1.08 (Revenue 2.89b / 2.68b) |
| TATA: -0.01 (NI -366.0m - CFO 2.02b) / TA 413.55b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of CRBG shares?
As of March 26, 2026, the stock is trading at USD 24.17 with a total of 3,769,563 shares traded.
Over the past week, the price has changed by +1.17%, over one month by -11.17%, over three months by -20.14% and over the past year by -24.84%.
Over the past week, the price has changed by +1.17%, over one month by -11.17%, over three months by -20.14% and over the past year by -24.84%.
Is CRBG a buy, sell or hold?
Corebridge Financial has received a consensus analysts rating of 4.07.
Therefore, it is recommended to buy CRBG.
- StrongBuy: 6
- Buy: 5
- Hold: 2
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the CRBG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 36.9 | 52.8% |
| Analysts Target Price | 36.9 | 52.8% |
CRBG Fundamental Data Overview March 26, 2026
P/E Forward = 4.6253
P/S = 0.6361
P/B = 0.8786
Revenue TTM = 2.89b USD
EBIT TTM = 11.0m USD
EBITDA TTM = 567.0m USD
Long Term Debt = 10.91b USD (from longTermDebt, last quarter)
Short Term Debt = 9.36b USD (from shortTermDebt, last quarter)
Debt = 10.91b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.46b USD (from netDebt column, last quarter)
Enterprise Value = -43.79b USD (11.84b + Debt 10.91b - CCE 66.54b)
Interest Coverage Ratio = 0.02 (Ebit TTM 11.0m / Interest Expense TTM 552.0m)
EV/FCF = -21.67x (Enterprise Value -43.79b / FCF TTM 2.02b)
FCF Yield = -4.62% (FCF TTM 2.02b / Enterprise Value -43.79b)
FCF Margin = 69.96% (FCF TTM 2.02b / Revenue TTM 2.89b)
Net Margin = -12.67% (Net Income TTM -366.0m / Revenue TTM 2.89b)
Gross Margin = 80.89% ((Revenue TTM 2.89b - Cost of Revenue TTM 552.0m) / Revenue TTM)
Gross Margin QoQ = 81.67% (prev 81.35%)
Tobins Q-Ratio = -0.11 (set to none) (Enterprise Value -43.79b / Total Assets 413.55b)
Interest Expense / Debt = 1.21% (Interest Expense 132.0m / Debt 10.91b)
Taxrate = 17.82% (173.0m / 971.0m)
NOPAT = 9.04m (EBIT 11.0m * (1 - 17.82%))
Current Ratio = 2.84 (Total Current Assets 67.19b / Total Current Liabilities 23.65b)
Debt / Equity = 0.83 (Debt 10.91b / totalStockholderEquity, last quarter 13.20b)
Debt / EBITDA = 18.45 (Net Debt 10.46b / EBITDA 567.0m)
Debt / FCF = 5.18 (Net Debt 10.46b / FCF TTM 2.02b)
Total Stockholder Equity = 12.76b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.09% (Net Income -366.0m / Total Assets 413.55b)
RoE = -2.87% (Net Income TTM -366.0m / Total Stockholder Equity 12.76b)
RoCE = 0.05% (EBIT 11.0m / Capital Employed (Equity 12.76b + L.T.Debt 10.91b))
RoIC = 0.04% (NOPAT 9.04m / Invested Capital 24.03b)
WACC = 6.11% (E(11.84b)/V(22.75b) * Re(10.83%) + D(10.91b)/V(22.75b) * Rd(1.21%) * (1-Tc(0.18)))
Discount Rate = 10.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -10.06%
[DCF] Terminal Value 85.19% ; FCFF base≈2.07b ; Y1≈1.95b ; Y5≈1.82b
[DCF] Fair Price = 87.42 (EV 52.57b - Net Debt 10.46b = Equity 42.11b / Shares 481.7m; r=6.11% [WACC]; 5y FCF grow -7.79% → 3.0% )
EPS Correlation: -38.41 | EPS CAGR: -32.65% | SUE: 0.13 | # QB: 0
Revenue Correlation: 15.59 | Revenue CAGR: 15.17% | SUE: -2.75 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.26 | Chg7d=-0.006 | Chg30d=-0.028 | Revisions Net=-5 | Analysts=13
EPS current Year (2026-12-31): EPS=5.10 | Chg7d=-0.017 | Chg30d=-0.113 | Revisions Net=-6 | Growth EPS=+15.4% | Growth Revenue=+5.4%
EPS next Year (2027-12-31): EPS=5.89 | Chg7d=-0.016 | Chg30d=-0.157 | Revisions Net=-6 | Growth EPS=+15.6% | Growth Revenue=+5.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 5 Down within 30d for Next Quarter)
P/S = 0.6361
P/B = 0.8786
Revenue TTM = 2.89b USD
EBIT TTM = 11.0m USD
EBITDA TTM = 567.0m USD
Long Term Debt = 10.91b USD (from longTermDebt, last quarter)
Short Term Debt = 9.36b USD (from shortTermDebt, last quarter)
Debt = 10.91b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.46b USD (from netDebt column, last quarter)
Enterprise Value = -43.79b USD (11.84b + Debt 10.91b - CCE 66.54b)
Interest Coverage Ratio = 0.02 (Ebit TTM 11.0m / Interest Expense TTM 552.0m)
EV/FCF = -21.67x (Enterprise Value -43.79b / FCF TTM 2.02b)
FCF Yield = -4.62% (FCF TTM 2.02b / Enterprise Value -43.79b)
FCF Margin = 69.96% (FCF TTM 2.02b / Revenue TTM 2.89b)
Net Margin = -12.67% (Net Income TTM -366.0m / Revenue TTM 2.89b)
Gross Margin = 80.89% ((Revenue TTM 2.89b - Cost of Revenue TTM 552.0m) / Revenue TTM)
Gross Margin QoQ = 81.67% (prev 81.35%)
Tobins Q-Ratio = -0.11 (set to none) (Enterprise Value -43.79b / Total Assets 413.55b)
Interest Expense / Debt = 1.21% (Interest Expense 132.0m / Debt 10.91b)
Taxrate = 17.82% (173.0m / 971.0m)
NOPAT = 9.04m (EBIT 11.0m * (1 - 17.82%))
Current Ratio = 2.84 (Total Current Assets 67.19b / Total Current Liabilities 23.65b)
Debt / Equity = 0.83 (Debt 10.91b / totalStockholderEquity, last quarter 13.20b)
Debt / EBITDA = 18.45 (Net Debt 10.46b / EBITDA 567.0m)
Debt / FCF = 5.18 (Net Debt 10.46b / FCF TTM 2.02b)
Total Stockholder Equity = 12.76b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.09% (Net Income -366.0m / Total Assets 413.55b)
RoE = -2.87% (Net Income TTM -366.0m / Total Stockholder Equity 12.76b)
RoCE = 0.05% (EBIT 11.0m / Capital Employed (Equity 12.76b + L.T.Debt 10.91b))
RoIC = 0.04% (NOPAT 9.04m / Invested Capital 24.03b)
WACC = 6.11% (E(11.84b)/V(22.75b) * Re(10.83%) + D(10.91b)/V(22.75b) * Rd(1.21%) * (1-Tc(0.18)))
Discount Rate = 10.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -10.06%
[DCF] Terminal Value 85.19% ; FCFF base≈2.07b ; Y1≈1.95b ; Y5≈1.82b
[DCF] Fair Price = 87.42 (EV 52.57b - Net Debt 10.46b = Equity 42.11b / Shares 481.7m; r=6.11% [WACC]; 5y FCF grow -7.79% → 3.0% )
EPS Correlation: -38.41 | EPS CAGR: -32.65% | SUE: 0.13 | # QB: 0
Revenue Correlation: 15.59 | Revenue CAGR: 15.17% | SUE: -2.75 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.26 | Chg7d=-0.006 | Chg30d=-0.028 | Revisions Net=-5 | Analysts=13
EPS current Year (2026-12-31): EPS=5.10 | Chg7d=-0.017 | Chg30d=-0.113 | Revisions Net=-6 | Growth EPS=+15.4% | Growth Revenue=+5.4%
EPS next Year (2027-12-31): EPS=5.89 | Chg7d=-0.016 | Chg30d=-0.157 | Revisions Net=-6 | Growth EPS=+15.6% | Growth Revenue=+5.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 5 Down within 30d for Next Quarter)